Login / Signup

Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs.

Namrata SinghLaura S GoldJiha LeeKatherine D WyshamJames S AndrewsUna E MakrisBryant R EnglandMichael D GeorgeJoshua F BakerJeffrey JarvikPatrick J HeagertySiddharth Singh
Published in: Arthritis care & research (2024)
Frailty is an important predictor for the risk of adverse outcomes among patients with RA treated with biologic or targeted-synthetic DMARDs.
Keyphrases
  • rheumatoid arthritis
  • disease activity
  • cancer therapy
  • rheumatoid arthritis patients
  • community dwelling
  • ankylosing spondylitis
  • newly diagnosed
  • systemic sclerosis
  • drug induced